Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 104,300 shares, a decline of 19.3% from the October 15th total of 129,200 shares. Based on an average daily trading volume, of 438,200 shares, the days-to-cover ratio is currently 0.2 days.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its stake in Aptevo Therapeutics by 18.7% during the 2nd quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 11,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Aptevo Therapeutics during the 4th quarter worth $29,000. Virtu Financial LLC purchased a new stake in Aptevo Therapeutics during the 2nd quarter worth about $46,000. Vanguard Group Inc. lifted its holdings in Aptevo Therapeutics by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock worth $1,414,000 after buying an additional 16,337 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Aptevo Therapeutics during the 3rd quarter worth about $51,000. 8.06% of the stock is owned by institutional investors and hedge funds.
Aptevo Therapeutics Price Performance
Shares of NASDAQ APVO opened at $0.18 on Tuesday. Aptevo Therapeutics has a twelve month low of $0.15 and a twelve month high of $7.20. The stock has a fifty day simple moving average of $0.33 and a 200-day simple moving average of $0.92.
Analysts Set New Price Targets
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.
- Five stocks we like better than Aptevo Therapeutics
- Best Restaurant Stocks to Invest in Now
- Bargain alert: 3 large caps with RSIs that scream oversold
- How to Invest in Fertilizer
- Compound your way to wealth with these retail stocks
- Dividend Payout Ratio Calculator
- Block proves it’s the triple threat fintech stock to own
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.